IDiyas

For the Inventor, By the Inventor

Osaka, Japan

Masakazu Ban

USPTO Granted Patents = 18

 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 38(Granted Patents)


Location History:

  • Osaka, JP (2001 - 2011)
  • Ikoma, JP (2009 - 2015)

Company Filing History:

goldMedal18 out of 281 
 
Santen Pharmaceutical Co., Ltd.
 patents

Years Active: 2001-2015

Loading Chart...
Loading Chart...
18 patents (USPTO):
1. 9029572 - 3-hydroxy-6H-benzo [C] chromene-6-one derivative and manufacturing method thereof (2015-05-12),
2. 8802869 - 3-hydroxy-6H-benzo [c] chromene-6-one derivative and manufacturing method thereof (2014-08-12),
3. 8518973 - Compounds having 4-pyridylalkylthio group as a substituent (2013-08-27),
4. 8207194 - Compounds having a 4-pyridylalkylthio group as a substituent (2012-06-26),
5. 8063034 - Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity (2011-11-22),
6. 7923461 - TNF-α production inhibitors (2011-04-12),
7. 7534802 - Compounds having 4-pyridylalkylthio group as substituent (2009-05-19),
8. 7491739 - TNF-α production inhibitors (2009-02-17),
9. 7345064 - TNF-α production inhibitors (2008-03-18),
10. 7098226 - TNF-α production inhibitors (2006-08-29),
11. 6960575 - Thiazine derivatives (2005-11-01),
12. 6730784 - Urea derivatives useful as synthetic intermediates (2004-05-04),
13. 6713472 - Thiazine or pyrazine derivatives (2004-03-30),
14. 6683200 - N-substituted-N′-substituted urea derivatives and pharmaceutical compositions containing the derivatives (2004-01-27),
15. 6534499 - N-substituted-N′-substituted urea derivatives and the use thereof as TNF-&agr; production inhibitory agents (2003-03-18),

Title: The Innovative Contributions of Masakazu Ban

Introduction

Masakazu Ban is a prominent inventor based in Osaka, Japan, known for his significant contributions to the field of pharmaceuticals. With a remarkable 18 patents to his name, Ban has made substantial advancements in drug formulation and synthesis methods. His innovative approaches have left a lasting impact on the pharmaceutical industry.

Latest Patents

One of Masakazu Ban's notable patents involves a method for manufacturing a compound called 3-hydroxy-6H-benzo [C] chromene-6-one derivative. This patent describes a process in which specific compounds react in the presence of carbonate and copper salts, or with hydroxide salts, carbonate, and copper salts. This innovation highlights his focus on improving the efficiency and effectiveness of pharmaceutical compounds.

Another of his recent patents reiterates the same method for manufacturing the 3-hydroxy-6H-benzo [c] chromene-6-one derivative, emphasizing its importance and potential applications in medicinal chemistry.

Career Highlights

Ban's career is marked by his association with Santen Pharmaceutical Co., Ltd., where he has been instrumental in research and development efforts. His work has been characterized by a dedication to advancing medicinal products that cater to various health needs. His extensive portfolio of patents showcases his innovative thinking and problem-solving capabilities within the industry.

Collaborations

Throughout his career, Masakazu Ban has collaborated with several esteemed colleagues, including Masato Horiuchi and Hiroshi Suhara. These collaborations have further enriched his research endeavors, leading to significant breakthroughs in pharmaceutical applications and enhancing the impact of their collective work in the industry.

Conclusion

Masakazu Ban's contributions to innovation and invention in pharmaceuticals are commendable. With a total of 18 patents to his name and a focus on drug synthesis methods, his work continues to push the boundaries of medical science. His collaborations and dedication exemplify the spirit of innovation that drives advancements in healthcare. As the pharmaceutical industry evolves, inventors like Ban remain at the forefront, shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…